US20080287392A1 - Wound-Healing Pharmaceutical Compositions in the Form of a Cream Based on Amino Acids and Sodium Hyaluronate - Google Patents
Wound-Healing Pharmaceutical Compositions in the Form of a Cream Based on Amino Acids and Sodium Hyaluronate Download PDFInfo
- Publication number
- US20080287392A1 US20080287392A1 US12/091,462 US9146206A US2008287392A1 US 20080287392 A1 US20080287392 A1 US 20080287392A1 US 9146206 A US9146206 A US 9146206A US 2008287392 A1 US2008287392 A1 US 2008287392A1
- Authority
- US
- United States
- Prior art keywords
- proline
- leucine
- lysine
- sodium hyaluronate
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920002385 Sodium hyaluronate Polymers 0.000 title claims abstract description 17
- 229940010747 sodium hyaluronate Drugs 0.000 title claims abstract description 17
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 title claims abstract description 17
- 239000006071 cream Substances 0.000 title claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 10
- 230000029663 wound healing Effects 0.000 title abstract description 5
- 150000001413 amino acids Chemical class 0.000 title abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 26
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 25
- 229960003136 leucine Drugs 0.000 claims description 17
- 229960002429 proline Drugs 0.000 claims description 17
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 15
- 206010052428 Wound Diseases 0.000 claims description 15
- 208000027418 Wounds and injury Diseases 0.000 claims description 15
- 239000004471 Glycine Substances 0.000 claims description 13
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 235000019454 L-leucine Nutrition 0.000 claims description 10
- 239000004395 L-leucine Substances 0.000 claims description 10
- 229930182821 L-proline Natural products 0.000 claims description 10
- 239000004472 Lysine Substances 0.000 claims description 10
- 229960003646 lysine Drugs 0.000 claims description 10
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 7
- 235000018977 lysine Nutrition 0.000 claims description 7
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 6
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 4
- 230000003902 lesion Effects 0.000 claims description 4
- 230000008929 regeneration Effects 0.000 claims description 4
- 238000011069 regeneration method Methods 0.000 claims description 4
- 235000019766 L-Lysine Nutrition 0.000 claims description 3
- 206010054828 Rectal lesion Diseases 0.000 claims description 3
- 208000002847 Surgical Wound Diseases 0.000 claims description 3
- 206010048937 Vaginal lesion Diseases 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 229960002449 glycine Drugs 0.000 claims description 3
- 230000009759 skin aging Effects 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 9
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 claims 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 2
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical group CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims 2
- 230000032683 aging Effects 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 6
- 230000035876 healing Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000000856 Postphlebitic Syndrome Diseases 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- -1 pH regulators Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- UPOYFZYFGWBUKL-UHFFFAOYSA-N amiphenazole Chemical compound S1C(N)=NC(N)=C1C1=CC=CC=C1 UPOYFZYFGWBUKL-UHFFFAOYSA-N 0.000 description 1
- 229950001798 amiphenazole Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000000527 greater trochanter Anatomy 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009519 pharmacological trial Methods 0.000 description 1
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000006833 reintegration Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to wound-healing pharmaceutical compositions in the form of a cream based on amino acids and sodium hyaluronate.
- Bedsores and chronic ulcerous wounds are usually treated with gentle massage to restore the circulation, possibly with mechanical removal of the necrotic tissue and cleansing with soap (which can cause oedema or dehydration), or with hydrophilic polymers, hydrogen peroxide or alcohol rubs (which can cause damage because the removal of the fats in the cutaneous tissue dries and cracks the skin).
- the invention therefore relates to wound-healing pharmaceutical compositions in the form of a cream, containing, as active ingredient, a combination of:
- compositions according to the invention contain glycine, L-proline and sodium hyaluronate, and possibly L-lysine in hydrochloride form, and L-leucine.
- compositions according to the invention have proved a surprising adjuvant effect in promoting the healing of ordinary wounds, including surgical wounds, vaginal and rectal lesions, buccal wounds and lesions, including those from dental surgery, as well as wounds which cannot be stitched and have seriously damaged the dermis, including loss of skin substance, such as chronic ulcerous wounds, serious burns and bedsores.
- compositions of the invention promote the elimination of necrotic tissue, thus facilitating more rapid regeneration of the tissues, and maintain the ideal humidity conditions to aid re-epithelialisation of the skin lesions, at the same time preventing the spread of germs.
- compositions of the invention are also useful for the treatment and/or prevention of skin aging.
- compositions of the invention will be applied to the affected area after removing any foreign material by thorough washing with a hydrogen peroxide solution or saline solution, and removing any excess blood with sterile gauze.
- compositions of the invention will be applied to the affected area possibly after suitable cleansing of the affected area with appropriate cleansing formulations.
- compositions according to the invention will contain the various active ingredients within the following percentage ranges by weight:
- compositions according to the invention will contain the various active ingredients in the following percentages by weight:
- compositions according to the invention can be formulated suitably for the topical administration in the form of a cream, and prepared according to conventional methods well known in pharmaceutical technology, such as those described in Remington's Pharmaceutical Handbook, Mack Publishing Co., N.Y., USA, using excipients, solubilisers, emollients, stabilisers, emulsifiers, pH regulators, and preservatives acceptable for their final use.
- compositions of the invention to heal chronic sores in elderly patients, diabetics and patients with vascular disease was evaluated.
- the treatment was given three/four times a week, depending on the severity of the lesions, by spreading the cream on the wound.
- the bedsores had to have a de-epithelialised area of over 10 cm 2 which had already been treated by conventional means for over 4 months, without any evident results.
- the type of bandage was irrelevant.
- the cream compositions according to the invention obtained healing indexes (expressed as % improvement) exceeding 80% by comparison with conventional treatment.
- compositions of the invention also proved to be very effective in the treatment of ordinary wounds, including surgical wounds, vaginal and rectal lesions as well as in the treatment and/or prevention of skin aging.
- compositions of the invention also proved to be very effective in the treatment of buccal wounds and lesions, including those from dental surgery.
- % INGREDIENTS Composition Purified water 82.27 Sodium hyaluronate 1.33 Glycine 1.00 L-Proline 0.75 L-Leucine 0.15 L-Lysine HCl 0.10 Cetyl stearyl octanoate (Saboderm CSO) 6.00 Acrylic acid and vinyl ester copolymer (Stabylen30) 0.30 Cetyl stearyl alcohol (Lanette O) 4.00 Potassium cetyl phosphate (Amphisol K) 3.00 Imidazolidinyl urea (Preservative G) 0.30 Phenoxyethanol-parabens (Sepicide Hb2) 0.60 32% Sodium hydroxide 0.20
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
This invention relates to wound-healing pharmaceutical or cosmetic (anti-skin aging) compositions in the form of a cream based on amino acids and sodium hyaluronate.
Description
- The present invention relates to wound-healing pharmaceutical compositions in the form of a cream based on amino acids and sodium hyaluronate.
- In the absence of suitable preventive actions, patients who are paralysed or bedridden for long periods are liable to ischaemic necrosis and ulceration of the tissues covering projecting bones, especially in the sacral, ischial, malleolar, heel and great trochanter regions.
- Bedsores and chronic ulcerous wounds are usually treated with gentle massage to restore the circulation, possibly with mechanical removal of the necrotic tissue and cleansing with soap (which can cause oedema or dehydration), or with hydrophilic polymers, hydrogen peroxide or alcohol rubs (which can cause damage because the removal of the fats in the cutaneous tissue dries and cracks the skin).
- Serious burns also require debridement of the affected area and removal of necrotic tissue.
- It has now been found that the combination of some amino acids with sodium hyaluronate is particularly effective in promoting the process of cell reintegration which forms the basis for fast wound-healing, aiding the reconstruction of connective tissue and the consequent regeneration of epithelial cells.
- The invention therefore relates to wound-healing pharmaceutical compositions in the form of a cream, containing, as active ingredient, a combination of:
- a) glycine and proline;
- b) sodium hyaluronate; and possibly;
- c) lysine and leucine.
- More particularly, the compositions according to the invention contain glycine, L-proline and sodium hyaluronate, and possibly L-lysine in hydrochloride form, and L-leucine.
- The compositions according to the invention have proved a surprising adjuvant effect in promoting the healing of ordinary wounds, including surgical wounds, vaginal and rectal lesions, buccal wounds and lesions, including those from dental surgery, as well as wounds which cannot be stitched and have seriously damaged the dermis, including loss of skin substance, such as chronic ulcerous wounds, serious burns and bedsores.
- The compositions of the invention promote the elimination of necrotic tissue, thus facilitating more rapid regeneration of the tissues, and maintain the ideal humidity conditions to aid re-epithelialisation of the skin lesions, at the same time preventing the spread of germs.
- The compositions of the invention are also useful for the treatment and/or prevention of skin aging.
- The compositions of the invention will be applied to the affected area after removing any foreign material by thorough washing with a hydrogen peroxide solution or saline solution, and removing any excess blood with sterile gauze.
- For the vaginal and rectal administration, the compositions of the invention will be applied to the affected area possibly after suitable cleansing of the affected area with appropriate cleansing formulations.
- The compositions according to the invention will contain the various active ingredients within the following percentage ranges by weight:
-
- glycine 0.5 to 2%;
- L-proline: 0.2 to 1.5%;
- sodium hyaluronate: 0.5 to 3%;
- and possibly
-
- L-lysine hydrochloride: 0.05 to 1%;
- L-leucine: 0.05 to 0.3%.
- According to a preferred aspect, the compositions according to the invention will contain the various active ingredients in the following percentages by weight:
-
- glycine 1%;
- L-proline: 0.75%;
- sodium hyaluronate: 1.33%;
- and possibly
-
- L-lysine hydrochloride: 0.1%;
- L-leucine: 0.15%.
- The compositions according to the invention can be formulated suitably for the topical administration in the form of a cream, and prepared according to conventional methods well known in pharmaceutical technology, such as those described in Remington's Pharmaceutical Handbook, Mack Publishing Co., N.Y., USA, using excipients, solubilisers, emollients, stabilisers, emulsifiers, pH regulators, and preservatives acceptable for their final use.
- Pharmacological Trial
- The ability of the compositions of the invention to heal chronic sores in elderly patients, diabetics and patients with vascular disease was evaluated.
- In particular, 32 elderly patients suffering from bedsores, 31 Type II diabetics with ulcers extending to the lower limbs, and 38 patients with post-phlebitic ulcers were evaluated.
- The treatment was given three/four times a week, depending on the severity of the lesions, by spreading the cream on the wound.
- The bedsores had to have a de-epithelialised area of over 10 cm2 which had already been treated by conventional means for over 4 months, without any evident results. The type of bandage was irrelevant.
- The sore was clinically evaluated and photographed before treatment in the fourth and eighth weeks of the trial. “Healing” was defined as closing of the wounds, and “improvement” as a reduction in size of the treated area exceeding 70% of the initial area.
- By the fourth week of treatment 20 patients showed an improvement, namely a reduction in size of the sore of over 70%, and 3 were completely healed; by the end of the observation period (8th week), 16 patients were healed, 12 had improved and 4 patients presented a reduction of under 50% in the de-epithelialised area.
- Of the 31 diabetics with ulcers of various areas and depths, which had already been treated unsuccessfully for at least four months prior to our study, 9 were healed after four weeks' treatment, and another 16 no longer presented ulcerated areas by the end of treatment period. In 6 particularly serious cases there was an improvement, but the sore was still present by the end of the 8th week of treatment.
- In patients with post-phlebitic ulcers who had already undergone conventional treatment for at least two months with no result, the administration of the cream compositions according to the invention led to healing within one month in 15 patients and by the end of treatment (8th week) in another 19 patients, making a total of 34 out of 38 treated.
- In conclusion, in the case of bedsores, diabetic and post-phlebitic skin ulcers, the cream compositions according to the invention obtained healing indexes (expressed as % improvement) exceeding 80% by comparison with conventional treatment.
- The compositions of the invention also proved to be very effective in the treatment of ordinary wounds, including surgical wounds, vaginal and rectal lesions as well as in the treatment and/or prevention of skin aging.
- The compositions of the invention also proved to be very effective in the treatment of buccal wounds and lesions, including those from dental surgery.
- An example of a cream formulation according to the invention is set out below.
-
-
% INGREDIENTS Composition Purified water 82.27 Sodium hyaluronate 1.33 Glycine 1.00 L-Proline 0.75 L-Leucine 0.15 L-Lysine HCl 0.10 Cetyl stearyl octanoate (Saboderm CSO) 6.00 Acrylic acid and vinyl ester copolymer (Stabylen30) 0.30 Cetyl stearyl alcohol (Lanette O) 4.00 Potassium cetyl phosphate (Amphisol K) 3.00 Imidazolidinyl urea (Preservative G) 0.30 Phenoxyethanol-parabens (Sepicide Hb2) 0.60 32% Sodium hydroxide 0.20
Claims (14)
1-6. (canceled)
7. A pharmaceutical composition in form of a cream, the pharmaceutical composition containing as active ingredient a combination of:
a) glycine and proline; and
b) sodium hyaluronate
8. The pharmaceutical composition of claim 7 , the composition further comprising as active ingredient:
c) lysine and leucine.
9. The pharmaceutical composition of claim 7 , wherein proline is L-proline, and wherein glycine, L-proline and sodium hyaluronate are comprised within the following percentage ranges by weight:
glycine 0.5 to 2%;
L-proline: 0.2 to 1.50%; and
sodium hyaluronate: 0.5 to 3%;
10. The pharmaceutical composition of claim 8 , wherein lysine is L-lysine, leucine is L-leucine, and wherein L-lysine and L-leucine are comprised within the following percentage ranges by weight:
L-lysine hydrochloride: 0.05 to 1%; and
L-leucine: 0.05 to 0.3%.
11. The pharmaceutical composition of claim 7 , wherein proline is L-proline, and wherein glycine, L-proline and sodium hyaluronate have the following percentage ranges by weight:
glycine 1%;
L-proline: 0.75%; and
sodium hyaluronate: 1.33%;
12. The pharmaceutical composition of claim 8 , wherein lysine is L-lysine, leucine is L-leucine and wherein L-lysine and L-leucine have the following percentage ranges by weight:
L-lysine hydrochloride 0.1%; and
L-leucine: 0.15%.
13. A method for treating a wound in a biological tissue, the method comprising
administering to the biological tissue a medicament in form of a cream, the medicament comprising a combination of
a) glycine and proline; and
b) sodium hyaluronate.
14. The method of claim 13 , wherein the medicament further comprises lysine and leucine.
15. The method of claim 13 , wherein, the wound is a surgical wound, a vaginal lesion, a rectal lesion, a buccal wound or lesion, a wound from dental surgery, a chronic ulcerous wound, a serious burn, a bedsore or a wound associated with skin aging.
16. A method to promote regeneration of epithelial cells of a vaginal or rectal tissue, the method comprising
administering to the vaginal or rectal tissue a medicament in form of a cream for vaginal or rectal administration, the medicament comprising a combination of
a) glycine and proline; and
b) sodium hyaluronate.
17. The method of claim 16 , wherein the medicament further comprises lysine and leucine.
18. A method to promote regeneration of epithelial cells of a buccal tissue, the method comprising
administering to the buccal tissue a medicament in form of a cream for buccal administration, the medicament comprising a combination of
a) glycine and proline; and
b) sodium hyaluronate.
19. The method of claim 18 , wherein the medicament further comprises lysine and leucine.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT002035A ITMI20052035A1 (en) | 2005-10-26 | 2005-10-26 | PHARMACEUTICAL COMPOSITIONS CYCLING IN THE FORM OF CREAM BASED ON AMINO ACIDS AND SODIUM HYALURONATE |
ITMI2005A002035 | 2005-10-26 | ||
PCT/EP2006/009966 WO2007048522A1 (en) | 2005-10-26 | 2006-10-16 | Wound-healing pharmaceutical compositions in the form of a cream based on amino acids and sodium hyaluronate |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/009966 A-371-Of-International WO2007048522A1 (en) | 2005-10-26 | 2006-10-16 | Wound-healing pharmaceutical compositions in the form of a cream based on amino acids and sodium hyaluronate |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/954,840 Continuation US8404661B2 (en) | 2005-10-26 | 2010-11-26 | Wound-healing pharmaceutical compositions in the form of a cream based on amino acids and sodium hyaluronate |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080287392A1 true US20080287392A1 (en) | 2008-11-20 |
Family
ID=37696025
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/091,462 Abandoned US20080287392A1 (en) | 2005-10-26 | 2006-10-16 | Wound-Healing Pharmaceutical Compositions in the Form of a Cream Based on Amino Acids and Sodium Hyaluronate |
US12/954,840 Active US8404661B2 (en) | 2005-10-26 | 2010-11-26 | Wound-healing pharmaceutical compositions in the form of a cream based on amino acids and sodium hyaluronate |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/954,840 Active US8404661B2 (en) | 2005-10-26 | 2010-11-26 | Wound-healing pharmaceutical compositions in the form of a cream based on amino acids and sodium hyaluronate |
Country Status (11)
Country | Link |
---|---|
US (2) | US20080287392A1 (en) |
EP (1) | EP1951219B1 (en) |
JP (1) | JP5203955B2 (en) |
KR (1) | KR101583746B1 (en) |
AT (1) | ATE451100T1 (en) |
CA (1) | CA2627214C (en) |
DE (1) | DE602006011048D1 (en) |
ES (1) | ES2335436T3 (en) |
IT (1) | ITMI20052035A1 (en) |
PL (1) | PL1951219T3 (en) |
WO (1) | WO2007048522A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080249065A1 (en) * | 2005-10-26 | 2008-10-09 | Franco Conti | Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate |
US20080261915A1 (en) * | 2005-10-26 | 2008-10-23 | Solartium Llc | Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate |
US20110071105A1 (en) * | 2005-10-26 | 2011-03-24 | Solartium Llc | Wound-healing pharmaceutical compositions in the form of a cream based on amino acids and sodium hyaluronate |
EP2504001B1 (en) | 2009-11-26 | 2015-03-04 | Professional Dietetics S.r.l. | Combination for the treatment of radiation- or chemotherapy-induced mucositis |
US9801807B2 (en) | 2012-12-13 | 2017-10-31 | Shamroc, Inc. | Topical formulations for increasing the dermal concentration of hyaluronic acid |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20110954A1 (en) * | 2011-05-26 | 2012-11-27 | Professional Dietetics Srl | COMBINATIONS FOR THE TREATMENT OF VAGINAL OR RECTAL MUCOSITES |
US8642665B2 (en) | 2011-12-16 | 2014-02-04 | Conopco, Inc. | Environmentally friendly, low whitening compositions |
IN2015DN02358A (en) | 2012-10-09 | 2015-09-04 | Sigma Tau Ind Farmaceuti | |
GR1008308B (en) | 2013-05-31 | 2014-10-02 | UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", | Local pharmaceutical and medi-tech compositions containing combinations of sucralfat, hyaluronic acid, arginine and one natural moistening factor |
ITMI20131660A1 (en) | 2013-10-08 | 2015-04-09 | Professional Dietetics Srl | USE OF A COMBINATION FOR THE PREVENTION OF MUCOSITES INDUCED BY RADIATION OR CHEMOTHERAPY |
WO2016088078A1 (en) | 2014-12-04 | 2016-06-09 | Professional Dietetics S.P.A. | Aminoacid-based composition for fibroelastin recovery in dermal connective tissues |
KR20200047220A (en) | 2018-10-27 | 2020-05-07 | 장정훈 | Pharmaceutical composition for the treatment of wound or diabetic foot/hand ulcers |
KR102072948B1 (en) | 2019-08-06 | 2020-02-04 | 주식회사 씨엔엘바이오텍 | Pharmaceutical Fermented composition for treatment of wound |
KR102072947B1 (en) | 2019-08-06 | 2020-02-04 | 주식회사 씨엔엘바이오텍 | Pharmaceutical compositions for promoting wound healing or skin regeneration |
WO2021191811A1 (en) | 2020-03-24 | 2021-09-30 | Acupharm Investments (Pty) Limited | A novel wound gel composition |
US20230148647A1 (en) * | 2020-09-02 | 2023-05-18 | Elastic Lab Inc. | Composition for promoting biosynthesis of elastin and collagen in connective tissue |
KR102226810B1 (en) | 2020-09-02 | 2021-03-15 | 주식회사 엘라스틱랩 | Composition for Promoting Biosynthesis of Elastin and Collagen in Connective tissue |
IT202100023921A1 (en) * | 2021-09-21 | 2023-03-21 | Casadei Elena Francesca | Composition for the analgesic and re-epithelializing treatment of the vulvo-vaginal and perineal tissue. |
WO2024096553A1 (en) * | 2022-11-02 | 2024-05-10 | 주식회사 엘지생활건강 | Complex for improving skin condition |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4707354A (en) * | 1985-06-17 | 1987-11-17 | Alpen Tau, Inc. | Mature skin treatment and protectant compositions and methods of using same |
US5741817A (en) * | 1994-07-22 | 1998-04-21 | Chowhan; Masood | Use of low molecular weight amino acids in ophthalmic compositions |
US20020013359A1 (en) * | 2000-06-07 | 2002-01-31 | Dioguardi Francesco Saverio | Pharmaceutical composition based on proline, glycine and lysine used in the therapy for the healing of tendon lesions and open wounds |
US20030021834A1 (en) * | 1996-08-07 | 2003-01-30 | Petito George D. | Method for use of hyaluronic acid in wound management |
US20030091652A1 (en) * | 2001-11-13 | 2003-05-15 | Suhail Ishaq | Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same |
US20040180025A1 (en) * | 2003-03-12 | 2004-09-16 | New Life Resources, Llc | Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations |
US20040265268A1 (en) * | 2001-08-18 | 2004-12-30 | Deepak Jain | Compositions and methods for skin rejuvenation and repair |
US20080249065A1 (en) * | 2005-10-26 | 2008-10-09 | Franco Conti | Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate |
US20080261915A1 (en) * | 2005-10-26 | 2008-10-23 | Solartium Llc | Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1240316B (en) * | 1990-02-21 | 1993-12-07 | Ricerca Di Schiena Del Dr. Michele G. Di Schiema & C. | COMPOSITIONS BASED ON HIGH MOLECULAR WEIGHT HYLURONIC ACID ADMINISTRABLE BY TOPIC FOR THE TREATMENT OF INFLAMMATIONS OF THE ORAL CABLE, FOR COSMETICS AND HYGIENE OF THE ORAL CABLE |
US6645948B2 (en) * | 1998-03-24 | 2003-11-11 | George D. Petito | Nutritional composition for the treatment of connective tissue |
IT1304191B1 (en) * | 1998-12-18 | 2001-03-08 | Solartium Establishment | PHARMACEUTICAL COMPOSITION BASED ON PROLIN, GLYCINE AND LYSINE USEFUL IN DENTAL THERAPY BOTH INJECTABLE AND INJECTABLE FORM |
FR2820635B1 (en) * | 2001-02-09 | 2005-01-21 | Genevrier Lab | PROCESS FOR THE PREPARATION OF A CREAM BASED ON HYALURONIC ACID |
ITTO20010804A1 (en) * | 2001-08-08 | 2003-02-08 | Professional Dietetics Srl | COMPOSITIONS BASED ON AMINO ACIDS, SUITABLE FOR THERAPY FOR CICATRIZATION AND / OR REPAIR OF INJURIES AND INJURIES, IN PARTICULAR FOR THE APP |
FR2864445B1 (en) * | 2003-12-30 | 2006-04-28 | Jean Noel Thorel | TOPICAL USE OF A COMPLEX NUTRIENT BASE |
ITMI20052035A1 (en) | 2005-10-26 | 2007-04-27 | Professional Dietetics Srl | PHARMACEUTICAL COMPOSITIONS CYCLING IN THE FORM OF CREAM BASED ON AMINO ACIDS AND SODIUM HYALURONATE |
-
2005
- 2005-10-26 IT IT002035A patent/ITMI20052035A1/en unknown
-
2006
- 2006-10-16 US US12/091,462 patent/US20080287392A1/en not_active Abandoned
- 2006-10-16 DE DE602006011048T patent/DE602006011048D1/en active Active
- 2006-10-16 PL PL06806303T patent/PL1951219T3/en unknown
- 2006-10-16 WO PCT/EP2006/009966 patent/WO2007048522A1/en active Application Filing
- 2006-10-16 ES ES06806303T patent/ES2335436T3/en active Active
- 2006-10-16 AT AT06806303T patent/ATE451100T1/en not_active IP Right Cessation
- 2006-10-16 KR KR1020087009860A patent/KR101583746B1/en active IP Right Grant
- 2006-10-16 EP EP06806303A patent/EP1951219B1/en active Active
- 2006-10-16 CA CA2627214A patent/CA2627214C/en active Active
- 2006-10-16 JP JP2008536973A patent/JP5203955B2/en active Active
-
2010
- 2010-11-26 US US12/954,840 patent/US8404661B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4707354A (en) * | 1985-06-17 | 1987-11-17 | Alpen Tau, Inc. | Mature skin treatment and protectant compositions and methods of using same |
US5741817A (en) * | 1994-07-22 | 1998-04-21 | Chowhan; Masood | Use of low molecular weight amino acids in ophthalmic compositions |
US20030021834A1 (en) * | 1996-08-07 | 2003-01-30 | Petito George D. | Method for use of hyaluronic acid in wound management |
US20020013359A1 (en) * | 2000-06-07 | 2002-01-31 | Dioguardi Francesco Saverio | Pharmaceutical composition based on proline, glycine and lysine used in the therapy for the healing of tendon lesions and open wounds |
US20040265268A1 (en) * | 2001-08-18 | 2004-12-30 | Deepak Jain | Compositions and methods for skin rejuvenation and repair |
US20030091652A1 (en) * | 2001-11-13 | 2003-05-15 | Suhail Ishaq | Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same |
US20040180025A1 (en) * | 2003-03-12 | 2004-09-16 | New Life Resources, Llc | Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations |
US20080249065A1 (en) * | 2005-10-26 | 2008-10-09 | Franco Conti | Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate |
US20080261915A1 (en) * | 2005-10-26 | 2008-10-23 | Solartium Llc | Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080249065A1 (en) * | 2005-10-26 | 2008-10-09 | Franco Conti | Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate |
US20080261915A1 (en) * | 2005-10-26 | 2008-10-23 | Solartium Llc | Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate |
US20110071105A1 (en) * | 2005-10-26 | 2011-03-24 | Solartium Llc | Wound-healing pharmaceutical compositions in the form of a cream based on amino acids and sodium hyaluronate |
US8404661B2 (en) | 2005-10-26 | 2013-03-26 | Professional Dietetics S.R.L. | Wound-healing pharmaceutical compositions in the form of a cream based on amino acids and sodium hyaluronate |
EP2504001B1 (en) | 2009-11-26 | 2015-03-04 | Professional Dietetics S.r.l. | Combination for the treatment of radiation- or chemotherapy-induced mucositis |
US20150079009A1 (en) * | 2009-11-26 | 2015-03-19 | Professional Dietetics S.R.L. | Combination for the treatment of radiation- or chemotherapy-induced mucositis |
US9220726B2 (en) * | 2009-11-26 | 2015-12-29 | Professional Dietetics S.R.L. | Combination for the treatment of radiation- or chemotherapy-induced mucositis |
US9801807B2 (en) | 2012-12-13 | 2017-10-31 | Shamroc, Inc. | Topical formulations for increasing the dermal concentration of hyaluronic acid |
US9895393B2 (en) | 2012-12-13 | 2018-02-20 | Shamroc, Inc. | Topical formulations for increasing the dermal concentration of hyaluronic acid |
Also Published As
Publication number | Publication date |
---|---|
EP1951219B1 (en) | 2009-12-09 |
EP1951219A1 (en) | 2008-08-06 |
CA2627214C (en) | 2015-03-10 |
PL1951219T3 (en) | 2010-05-31 |
ATE451100T1 (en) | 2009-12-15 |
ITMI20052035A1 (en) | 2007-04-27 |
DE602006011048D1 (en) | 2010-01-21 |
JP2009513585A (en) | 2009-04-02 |
WO2007048522A1 (en) | 2007-05-03 |
US20110071105A1 (en) | 2011-03-24 |
CA2627214A1 (en) | 2007-05-03 |
ES2335436T3 (en) | 2010-03-26 |
US8404661B2 (en) | 2013-03-26 |
JP5203955B2 (en) | 2013-06-05 |
KR20080068027A (en) | 2008-07-22 |
KR101583746B1 (en) | 2016-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8404661B2 (en) | Wound-healing pharmaceutical compositions in the form of a cream based on amino acids and sodium hyaluronate | |
US8426384B2 (en) | Wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate | |
US9962402B2 (en) | Healing composition for topical application | |
EA018425B1 (en) | Pharmaceutical, disinfectant or preservation extract of trigonella foenum-graecum, method for preparing and use thereof | |
US20100284951A1 (en) | Novel compositions for the treatment of wounds and skin care | |
US20200405637A1 (en) | Oil-based wound care compositions and methods | |
WO2020144564A1 (en) | Composition for the treatment of skin lesions and irritations | |
US20190216871A1 (en) | Diabetic foot cream | |
US11696907B2 (en) | Wound healing composition | |
JP2018521992A5 (en) | ||
US20020176876A1 (en) | Topical therapeutic skin care system | |
ITMI941680A1 (en) | VEGETABLE EXTRACT AGAINST BURNS | |
TW202104247A (en) | Composition and methods for promoting and treating chronic wound healing | |
MX2013004077A (en) | Pharmaceutical composition based on centella asiatica (hydrocotyle asiatica l.) for treating lower limbs ulcers. | |
KR100289906B1 (en) | Dermatological composition | |
JP2004262772A (en) | Glycyrrhizin-containing percutaneous pharmaceutical preparation | |
John Amalan | A clinical study of comparision between efficacy of topical sucralfate and conventional dressing in the managment of diabetic ulcer in Tirunelveli Medical College | |
KR20030028600A (en) | Composition for skin washing | |
Aurif | A prospectiv study of comparision between efficacy of topical sucralfate and conventional dressings in the management of chronic lower limb ulcers | |
MXPA05007566A (en) | Patch for topical application on keloid and hypertrophic scars. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SOLARTIUM LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONTI, FRANCO;REEL/FRAME:020853/0650 Effective date: 20080317 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: PROFESSIONAL DIETETICS S.R.L., ITALY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SOLARTIUM ENTERPRISES LIMITED;REEL/FRAME:026222/0618 Effective date: 20110117 |